RE
LOGC

RBC Europe’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

RBC Europe’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-275
Closed -$1.26K – 1246
2021
Q3 		$1.26K Hold
275
– – ﹤0.01% 1168
2021
Q2 		$1.22K Hold
275
– – ﹤0.01% 1163
2021
Q1 		$2K Hold
275
– – ﹤0.01% 1078
2020
Q4 		$2.1K Hold
275
– – ﹤0.01% 1045
2020
Q3 		$2.5K Hold
275
– – ﹤0.01% 968
2020
Q2 		$2.33K Hold
275
– – ﹤0.01% 947
2020
Q1 		$1.36K Buy
+275
New +$2.14K ﹤0.01% 940

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

RBC Europe's LOGC Position: Q4 2021 in Review

RBC Europe sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 275 shares — an estimated $1.26K sold.

RBC Europe first reported a position in LOGC in Q1 2020 and held it in 7 quarters. The position peaked at $2.5K in Q3 2020. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

  • RBC Europe reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 275 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.26K.
  • RBC Europe first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • RBC Europe's LogicBio Therapeutics, Inc. Common Stock position peaked at $2.5K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.